

**Supplemental Table 1. Studies excluded from the meta-analysis**

Author	Year	Reference	Reason for exclusion
Focke et al.	2018	<a href="#">Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):20-26.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
del Sordo, R.	2018	<a href="#">Histol Histopathol. 2018 Jan;33(1):81-88.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Webster et al.	2017	<a href="#">Cell Cycle. 2017;16(22):2176-2182.</a>	Not a study of the prognosis of PHH3.
Tracht et al.	2017	<a href="#">J Histochem Cytochem. 2017 Jul;65(7):399-405.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Suzuki et al.	2017	<a href="#">Brain Tumor Pathol. 2017 Oct;34(4):141-148.</a>	Not a study of the prognosis of PHH3.
Stalhammar et al.	2017	<a href="#">Histopathology. 2018 May;72(6):974-989.</a>	Not a study of the prognosis of PHH3.
Staettner et al.	2017	<a href="#">Hum Pathol. 2017 Jul;65:41-52.</a>	Not a study of the prognosis of PHH3.
Sillem et al.	2017	<a href="#">Breast Care (Basel). 2017 Sep;12(4):244-250.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Rompoti et al.	2017	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	Meeting Abstract.
Raninga et al.	2017	ANNALS OF ONCOLOGY	Meeting Abstract.
Parameswaran et al.	2017	JOURNAL OF CLINICAL ONCOLOGY	Meeting Abstract.
Nombela Blanco et al.	2017	ANNALS OF ONCOLOGY	Meeting Abstract.
Maitland et al.	2017	<a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L617435940">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L617435940</a>	Irrelevant research.
Li et al.	2017	<a href="#">Chinese Journal of Diagnostic Pathology</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Li et al.	2017	Journal of Mudanjiang Medical Universi	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Lee et al.	2017	<a href="#">Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):25-31.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Koch et al.	2017	<a href="#">Histochem Cell Biol. 2017 Aug;148(2):207-216.</a>	Irrelevant research.
Klieser et al.	2017	<a href="#">Hum Pathol. 2017 Jul;65:41-52.</a>	Not a study of the prognosis of PHH3.
Kim et al.	2017	<a href="#">Oncotarget. 2017 May 10;8(39):65064-65076.</a>	/
Ionkina et al.	2017	Front Oncol. 2017 May 15;7:94.	Meeting Abstract

Inoue et al.	2017 JOURNAL OF THORACIC ONCOLOGY S836-S837 P2.01-080	Meeting Abstract.
Infante et al.	2017 <u>Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326.</u>	Irrelevant research.
Husari et al.	2017 <u>Oxid Med Cell Longev. 2017;2017:6063201.</u>	Irrelevant research.
Han et al.	2017 <a href="http://www.smmu.edu.cn/">http://www.smmu.edu.cn/</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Gao et al.	2017 <u>Chinese Journal of Clinical and Experimental Pathology</u>	Not a study of the prognosis of PHH3.
Fernandez et al.	2017 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE	Meeting Abstract.
Fan et al.	2017 Journal of Taishan Medical College	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Ertan et al.	2017 <u>J Environ Pathol Toxicol Oncol. 2017;36(3):237-244.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Elmaci et al.	2017 <u>Clin Neuropathol. 2017 Nov/Dec;36(6):272-282.</u>	Not a study of the prognosis of PHH3.
Ding et al.	2017 MODERN PATHOLOGY	Meeting Abstract.
Deng et al.	2017 <u>Journal of Chengdu Medical College</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Chow et al.	2017 <u>Histopathology. 2017 Apr;70(5):746-755.</u>	/
Chavali et al.	2017 <u>Neurol India. 2017 Nov-Dec;65(6):1345-1349.</u>	Not a study of the prognosis of PHH3.
Bosch et al.	2017 <u>Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):543-547.</u>	Not a study of the prognosis of PHH3.
Blanco et al.	2017 ANNALS OF ONCOLOGY	Meeting Abstract.
Agarwal et al.	2017 <u>Am J Dermatopathol. 2017 Jul;39(7):504-507.</u>	Not a study of the prognosis of PHH3.
Zhu et al.	2016 <u>Oncotarget. 2016 Jul 19;7(29):45005-45014.</u>	/
Wong et al.	2016 AMERICAN JOURNAL OF GASTROENTEROLOGY	Meeting Abstract.
Winther et al.	2016 <u>Am J Clin Pathol. 2016 Oct;146(4):510-20.</u>	/
Wandler et al.	2016 <u>J Cutan Pathol. 2016 Nov;43(11):956-962.</u>	Not a study of the prognosis of PHH3.
Villani et al.	2016 <u>Ann Surg Oncol. 2016 Dec;23(Suppl 5):609-617. Epub 2016 Mar 28.</u>	Lack of survival analysis data (The patients were divided into three risk classes (G1, G2, and G3) according to the tumor grade, not the level of the PHH3 expression).
Varughese et al.	2016 <u>J Clin Pathol. 2016 Jan;69(1):26-34. doi: 10.1136/iclinpath-2015-202983. Epub 2015 Jul 17.</u>	Statistical defect.
Tokes et al.	2016 <u>Virchows Arch. 2016 Jun;468(6):675-86.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Saini et al.	2016 <u>PLoS One. 2016 Feb 10;11(2):e0148656.</u>	Not a study of the prognosis of PHH3.
Parsels et al.	2016 <u>Cell Cycle. 2016;15(5):730-9.</u>	Irrelevant research.

Ozturk et al.	2016 Endocr Pathol. 2016 Jun;27(2):162-70.	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
O'Halloran et al.	2016 PEDIATRIC BLOOD & CANCER	Meeting Abstract.
Nielsen et al.	2016 <u>Diagn Pathol.</u> 2016 Apr 9;11:35.	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Mross et al.	2016 <u>Cancer Chemother Pharmacol.</u> 2016 Aug;78(2):405-17.	Irrelevant research.
Merkel et al.	2016 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY	Meeting Abstract.
Marwaha et al.	2016 J Cutan Pathol. 2016 Dec;43(12):1186-1196.	Not a study of the prognosis of PHH3.
Lysak et al.	2016 PATHOLOGIA Volume 26,Period 2,Page 4-12.	Non-English literature
Li et al.	2016 ОРИГІНАЛЬНІ ДОСЛІДЖЕННЯ / ORIGINAL RESEARCHES	Non-English literature
Lee et al.	2016 <u>Cancer Lett.</u> 2016 Jul 1;376(2):310-7.	Irrelevant research.
Lamba et al.	2016 <u>PLoS One.</u> 2016 Feb 10;11(2):e0148656.	Not a study of the prognosis of PHH3.
Khan et al.	2016 <u>Clin Epigenetics.</u> 2016 Aug 31;8:88.	/
Kruger et al.	2016 <u>Am J Physiol Gastrointest Liver Physiol.</u> 2017 Sep 1;313(3):G180-G191.	Irrelevant research.
Islam et al.	2016 Target Oncol. 2016 Apr;11(2):209-27.	Irrelevant research.
Huang et al.	2016 <u>Hainan Medical Journal</u>	Not a study of the prognosis of PHH3.
Hanley et al.	2016 CANCER RESEARCH	Meeting Abstract.
Ginter et al.	2016 <u>Hum Pathol.</u> 2016 Mar;49:90-8.	Not a study of the prognosis of PHH3.
Duregon et al.	2016 <u>Oncotarget.</u> 2016 Apr 19;7(16):21190-8	Statistical defect.
Cornelia	2016 <u>Appl Immunohistochem Mol Morphol.</u> 2018 Jan;26(1):20-26.	Not a study of the prognosis of PHH3
Burke et al.	2016 CANCER RESEARCH	Meeting Abstract.
Bedekovics et al.	2016 VIRCHOWS ARCHIV	Meeting Abstract.
Wang et al.	2015 CANCER RESEARCH	Meeting Abstract.
Voss et al.	2015 Am J Surg Pathol. 2015 Jan;39(1):13-24.	Lack of survival analysis data (confidence interval of hazard risk estimate).
Uguen et al.	2015 <u>Virchows Arch.</u> 2015 Jul;467(1):47-54.	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Tetzlaff et al.	2015 <u>Clin Cosmet Investig Dermatol.</u> 2015 Jan 30;8:35-46.	Review.
Ramani et al.	2015 <u>J Histochem Cytochem.</u> 2015 Jun;63(6):397-407.	/
Pang et al.	2015 <u>Int J Clin Exp Pathol.</u> 2015 May 1;8(5):4418-26. eCollection 2015.	Not a study of the prognosis of PHH3.
Ottmann et al.	2015 <u>J Am Acad Dermatol.</u> 2015 Oct;73(4):637-44.	Not a study of the prognosis of PHH3.
Olar et al.	2015 <u>Brain Pathol.</u> 2015 May;25(3):266-75	/

Olar et al.	2015 <a href="#">Acta Neuropathol. 2015 Apr;129(4):585-96.</a>	Not a study of the prognosis of PHH3.
Moreno et al.	2015 <a href="#">Clin Cancer Res. 2015 Jan 15;21(2):267-73.</a>	Irrelevant research.
Massey et al.	2015 <a href="#">PLoS One. 2015 Jul 28;10(7):e0134306.</a>	Irrelevant research.
Martinez et al.	2015 <a href="#">PLoS One. 2015 Sep 23;10(9):e0138616.</a>	Irrelevant research.
Liu et al.	2015 <a href="#">Chinese Journal of Clinical and Experimental Pathology</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Liang et al.	2015 <a href="#">nt J Clin Exp Pathol. 2015 Jun 1;8(6):7196-202. eCollection 2015.</a>	Not a study of the prognosis of PHH3.
Li et al.	2015 CANCER RESEARCH	Meeting Abstract
Li et al.	2015 <a href="http://www.tijmu.edu.cn/">http://www.tijmu.edu.cn/</a>	Not a study of the prognosis of PHH3.
Konakazawa et al.	2015 <a href="#">Brain Res. 2015 Jul 21;1614:28-37. doi: 10.1016/j.brainres.2015.04.013. Epub 2015 Apr 17.</a>	Irrelevant research.
Iwasaki et al.	2015 <a href="#">Pathol Int. 2015 Aug;65(8):404-9. doi: 10.1111/pin.12305. Epub 2015 May 18.</a>	/
Ionkina et al.	2015 <a href="http://dx.doi.org/10.1158/1535-7163.TARG-15-C34">http://dx.doi.org/10.1158/1535-7163.TARG-15-C34</a>	Irrelevant research.
Henry et al.	2015 <a href="http://dx.doi.org/10.1158/1535-7163.TARG-15-B145">http://dx.doi.org/10.1158/1535-7163.TARG-15-B145</a>	Irrelevant research.
Gressot et al.	2015 <a href="#">Int J Cancer. 2015 May 1;136(9):2047-54.</a>	Irrelevant research.
Goltz et al.	2015 <a href="#">Pathology. 2015 Dec;47(7):629-36. doi: 10.1097/PAT.0000000000000320.</a>	/
Gebreyohannes et al.	2015 CANCER RESEARCH	Meeting Abstract
Gerring et al.	2015 <a href="#">Histopathology. 2015 Oct;67(4):538-47. doi: 10.1111/his.12678. Epub 2015 Mar 31.</a>	/
Gagner et al.	2015 CANCER RESEARCH	Meeting Abstract
Duregon et al.	2015 <a href="#">Neuro Oncol. 2015 May;17(5):663-9. doi: 10.1093/neuonc/nov002. Epub 2015 Feb 1.</a>	Not a study of the prognosis of PHH3.
Dessauvagie et al.	2015 <a href="#">Pathology. 2015 Jun;47(4):329-34. doi: 10.1097/PAT.0000000000000248.</a>	Not a study of the prognosis of PHH3.
Cui et al.	2015 <a href="#">Appl Immunohistochem Mol Morphol. 2015 Nov-Dec;23(10):689-95. doi: 10.1097/PAI.0000000000000137.</a>	Not a study of the prognosis of PHH3.
Cornillie et al.	2015 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72011489">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72011489</a>	Irrelevant research.
Brustmann et al.	2015 <a href="#">Int J Gynecol Pathol. 2015 Mar;34(2):187-95. doi: 10.1097/PGP.0000000000000116.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Ben et al.	2015 <a href="#">Clin Cancer Res. 2017 May 1;23(9):2289-2300. doi: 10.1158/1078-0432.CCR-16-1930. Epub 2016 Nov 17.</a>	Irrelevant research.
Alkhasawneh et al.	2015 <a href="#">Am J Clin Pathol. 2015 Mar;143(3):385-92. doi: 10.1309/AJCPAPH28VHZEKNQ.</a>	/
Zhou et al.	2014 <a href="#">Am J Dermatopathol. 2014 Jan;36(1):74-9. doi: 10.1097/DAD.0b013e3182914c64.</a>	Not a study of the prognosis of PHH3.
Xu	2014 <a href="http://www.sxmu.edu.cn/">http://www.sxmu.edu.cn/</a>	/
Wang et al.	2014 <a href="#">Chinese Journal of Tissue Engineering Research</a>	Not a study of the prognosis of PHH3.
Thareja et al.	2014 <a href="#">Am J Dermatopathol. 2014 Jan;36(1):64-7.</a>	Not a study of the prognosis of PHH3.
Seremet et al.	2014 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71772420">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71772420</a>	Lack of survival analysis data (hazard risk estimate or survival

---

Rehman et al.	2014 HEPATOLOGY	curve of OS, RFS, DFS). Meeting Abstract
Papanicolau-Sengos et al.	2014 MODERN PATHOLOGY	Meeting Abstract
Olar et al.	2014 MODERN PATHOLOGY	Meeting Abstract
Nowak et al.	2014 <u>World J Urol. 2014 Jun;32(3):703-7.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
McCormick et al.	2014 <u><a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71525112">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71525112</a></u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Lu et al.	2014 <u><a href="http://www.zju.edu.cn/">http://www.zju.edu.cn/</a></u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Lee et al.	2014 <u>Sci Rep. 2014 May 30;4:5122.</u>	Not a study of the prognosis of PHH3.
Lee et al.	2014 MODERN PATHOLOGY	Meeting Abstract
Kilgore et al.	2014 MODERN PATHOLOGY	Meeting Abstract
Kemmerling et al.	2014 <u>Oncol Lett. 2014 Mar;7(3):745-749. Epub 2014 Jan 15.</u>	Not a study of the prognosis of PHH3.
Henderson et al.	2014 MODERN PATHOLOGY	Meeting Abstract
<b>Henderson et al.</b>	2014 <u>J Cutan Pathol. 2014 Nov;41(11):846-52.</u>	Statistical defect.
Grachtchouk et al.	2014 JOURNAL OF INVESTIGATIVE DERMATOLOGY	Meeting Abstract
Duregon et al.	2014 <u>Mod Pathol. 2014 Sep;27(9):1246-54.</u>	/
Cullinane et al.	2014 <u>Nucl Med Biol. 2014 Feb;41(2):148-54.</u>	Irrelevant research.
Braun et al.	2014 <u>Int J Cancer. 2014 Jul 1;135(1):19-26.</u>	Irrelevant research.
Backer-Grondahl et al.	2014 <u>Int J Clin Exp Pathol. 2014 Sep 15;7(10):7206-19. eCollection 2014.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Yin et al.	2013 Maternal and Child Health Care of China	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Tetzlaff et al.	2013 <u>Mod Pathol. 2013 Sep;26(9):1153-60.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Nonaka et al.	2013 LABORATORY INVESTIGATION	Meeting Abstract
Nakashima et al.	2013 <u>Anticancer Res. 2013 Feb;33(2):461-7.</u>	No hazard risk (HR) estimate for esophageal squamous cell carcinoma.
Mills et al.	2013 <u>Am J Surg Pathol. 2013 May;37(5):634-42.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).

---

Li et al.	2013 <a href="#">Eur J Med Chem. 2013 Jul;65:151-7.</a>	Irrelevant research.
Kunos et al.	2013 <a href="#">Front Oncol. 2013 Sep 18;3:226.</a>	Irrelevant research.
Knutsvik et al.	2013 LABORATORY INVESTIGATION	Meeting Abstract
Klintman et al.	2013 <a href="#">PLoS One. 2013 Dec 4;8(12):e81902.</a>	/
Kikuchi et al.	2013 Cancer Research	Meeting Abstract
Karra et al.	2013 <a href="#">Bioorg Med Chem Lett. 2013 May 15;23(10):3081-7.</a>	Irrelevant research.
Ishizawa et al.	2013 BLOOD	Meeting Abstract
Idriss et al.	2013 <a href="#">J Cutan Pathol. 2013 Jun;40(6):557-63.</a>	Not a study of the prognosis of PHH3.
Hale et al.	2013 <a href="#">Am J Surg Pathol. 2013 Jun;37(6):882-9.</a>	The follow-up outcome is PFS. Our study did not include studies on PFS because of the small number of studies.
Gudlaugsson et al.	2013 <a href="#">Pol J Pathol. 2013 Apr;64(1):1-8.</a>	/
Fung et al.	2013 <a href="#">Acta Cytol. 2013;57(5):501-8.</a>	Not a study of the prognosis of PHH3.
Draganova-Tacheva et al.	2013 <a href="#">Acta Cytol. 2013;57(3):291-5.</a>	Not a study of the prognosis of PHH3.
Cui et al.	2013 <a href="#">Appl Immunohistochem Mol Morphol. 2015 Nov-Dec;23(10):689-95. doi: 10.1097/PAI.000000000000137.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Chen et al.	2013 <a href="#">Clinics (Sao Paulo). 2013 Jun;68(6):825-33.</a>	Irrelevant research.
Chen et al.	2013 <a href="#">J Chemother. 2013 Aug;25(4):229-38.</a>	Irrelevant research.
Braun et al.	2013 <a href="#">World J Urol. 2013 Dec;31(6):1489-95.</a>	Irrelevant research.
Armstrong et al.	2013 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71299310">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71299310</a>	Not a study of the prognosis of PHH3.
Aftimos et al.	2013 <a href="#">Cancer Chemother Pharmacol. 2016 Jan;77(1):99-108.</a>	Irrelevant research.
Washington et al.	2012 <a href="#">Sci Signal. 2012 Jul 24;5(234):ra52.</a>	Irrelevant research.
Sun et al.	2012 <a href="#">BMJ Open. 2012 Oct 12;2(5). pii: e001071.</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Stomper et al.	2012 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70662478">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70662478</a>	Irrelevant research.
Solomides et al.	2012 <a href="#">Acta Cytol. 2012;56(3):285-8.</a>	Not a study of the prognosis of PHH3.
Sini et al.	2012 CANCER RESEARCH	Meeting Abstract
Shumway et al.	2012 CANCER RESEARCH	Meeting Abstract
Schwarz et al.	2012 <a href="#">Cancer Prev Res (Phila). 2017 Oct;10(10):563-570.</a>	Irrelevant research.
Schimming et al.	2012 <a href="#">Am J Dermatopathol. 2012 May;34(3):266-9.</a>	Not a study of the prognosis of PHH3.
Olar et al.	2012 <a href="#">Curr Treat Options Oncol. 2012 Dec;13(4):417-36.</a>	Review.
Ma et al.	2012 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71003588">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71003588</a>	Irrelevant research.

Lloyd et al.	2012 LABORATORY INVESTIGATION	Meeting Abstract
Liu et al.	2012 Tianjin Medical Journal	Not a study of the prognosis of PHH3.
Li et al.	2012 <u>Brain Tumor Pathol. 2012 Jan;29(1):68-72.</u>	Case report.
Ladstein et al.	2012 <u>J Invest Dermatol. 2012 Apr;132(4):1247-52.</u>	/
Kudaybergenova et al.	2012 VIRCHOWS ARCHIV	Meeting Abstract
Knutsvik et al.	2012 VIRCHOWS ARCHIV	Meeting Abstract
Kalantarli et al.	2012 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L365686006">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L365686006</a>	Not a study of the prognosis of PHH3.
Kadaveru et al.	2012 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71091586">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71091586</a>	Irrelevant research.
Ishizawa et al.	2012 <u>Clin Neuropathol. 2012 May-Jun;31(3):146-51.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Ishihara et al.	2012 EUROPEAN JOURNAL OF CANCER	Meeting Abstract
Ikenberg et al.	2012 <u>J Cutan Pathol. 2012 Mar;39(3):324-30.</u>	Not a study of the prognosis of PHH3.
Hikichi et al.	2012 <u>Mol Cancer Ther. 2012 Mar;11(3):700-9.</u>	Irrelevant research.
Hightower et al.	2012 <u>Pituitary. 2012 Dec;15(4):556-61. doi: 10.1007/s11102-011-0367-3.</u>	The follow-up outcome is TTP. Our study did not include studies on TTP because of the small number of studies.
Gunia et al.	2012 <u>J Clin Pathol. 2012 Aug;65(8):715-20.</u>	Not a study of the prognosis of PHH3.
Gauchotte et al.	2012 <u>Am J Surg Pathol. 2012 Feb;36(2):283-91</u>	The follow-up outcome is PFS. Our study did not include studies on PFS because of the small number of studies.
Brunner et al.	2012 <u>Br J Cancer. 2012 Jun 26;107(1):84-90.</u>	/
Braun et al.	2012 VIRCHOWS ARCHIV	Meeting Abstract
Alferez et al.	2012 <u>Int J Oncol. 2012 Oct;41(4):1475-85.</u>	Irrelevant research.
Zou et al.	2011 <u>Cell Cycle. 2011 Mar 15;10(6):989-98. Epub 2011 Mar 15.</u>	Irrelevant research.
Verschraegen et al.	2011 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70609385">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70609385</a>	Irrelevant research.
Um et al.	2011 <a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70609306">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70609306</a>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Tsuta et al.	2011 <u>Am J Clin Pathol. 2011 Aug;136(2):252-9.</u>	Not a study of the prognosis of PHH3.
Silva et al.	2011 <u>Int J Gynecol Cancer. 2011 Jan;21(1):189-91.</u>	Review.
Shih et al.	2011 JOURNAL OF CLINICAL ONCOLOGY	Meeting Abstract
Phadke et al.	2011 <u>Am J Surg Pathol. 2011 May;35(5):656-69.</u>	Not a study of the prognosis of PHH3.
Patterson et al.	2011 BIOLOGY OF REPRODUCTION	Meeting Abstract
Olmos et al.	2011 <u>Clin Cancer Res. 2011 May 15;17(10):3420-30.</u>	Irrelevant research.

Margraf et al.	2011 <u>Neuro Oncol. 2011 Jul;13(7):767-74.</u>	The follow-up outcome is PFS. Our study did not include studies on PFS because of the small number of studies.
Ladstein et al.	2011 CANCER RESEARCH	Meeting Abstract
Hsu et al.	2011 <u>Dev Biol. 2011 Jun 15;354(2):242-52.</u>	Irrelevant research.
Horinaga et al.	2011 JOURNAL OF CLINICAL ONCOLOGY	Meeting Abstract
Horinaga et al.	2011 JOURNAL OF UROLOGY	Meeting Abstract
Habberstad et al.	2011 <u>Diagn Pathol. 2011 May 24;6:43.</u>	Not a study of the prognosis of PHH3.
Grundy et al.	2011 <u>BMC Cancer. 2011 Jun 16;11:254.</u>	Irrelevant research.
Gudlaugsson et al.	2011 <u>Mod Pathol. 2011 Apr;24(4):502-11.</u>	/
Diamond et al.	2011 CANCER RESEARCH	Meeting Abstract
Danaee et al.	2011 <u><a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70609300">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70609300</a></u>	Irrelevant research.
<b>Aune et al.</b>	2011 <u>Int J Clin Exp Pathol. 2011 Jun 20;4(5):444-53. Epub 2011 Jun 11.</u>	Statistical defect.
Angi et al.	2011 <u>Acta Ophthalmol. 2011 Mar;89(2):e155-60. doi: 10.1111/j.1755-3768.2009.01769.x.</u>	Not a study of the prognosis of PHH3.
Nasir et al.	2010 <u><a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70309910">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70309910</a></u>	Irrelevant research.
Marangoni et al.	2010 <u><a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70310394">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70310394</a></u>	Irrelevant research.
Ladstein et al.	2010 <u>BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.</u>	Repeated study by the same author.
Hayashi et al.	2010 <u><a href="http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70667855">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70667855</a></u>	Irrelevant research.
Grundy et al.	2010 <u>Mol Cancer Ther. 2010 Mar;9(3):661-72.</u>	Irrelevant research.
Glatz et al.	2010 <u>Am J Dermatopathol. 2010 Oct;32(7):643-9.</u>	Not a study of the prognosis of PHH3.
Casper et al.	2010 <u>Am J Dermatopathol. 2010 Oct;32(7):650-4.</u>	Not a study of the prognosis of PHH3.
Blackman et al.	2010 JOURNAL OF CLINICAL ONCOLOGY	Meeting Abstract
Veras et al.	2009 <u>Int J Gynecol Pathol. 2009 Jul;28(4):316-21.</u>	Not a study of the prognosis of PHH3.
Goodarzi et al.	2009 LABORATORY INVESTIGATION	Meeting Abstract
Gilmartin et al.	2009 <u>Cancer Res. 2009 Sep 1;69(17):6969-77.</u>	Irrelevant research.
Fukushima et al.	2009 <u>Brain Tumor Pathol. 2009;26(2):51-7.</u>	Not a study of the prognosis of PHH3.
Evason et al.	2009 LABORATORY INVESTIGATION	Meeting Abstract
Yoo-Jin et al.	2008 <u>Pathologe. 2008 Nov;29(6):428-33.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Shah et al.	2008 <u>Int J Gynecol Pathol. 2008 Oct;27(4):534-8.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Nasr et al.	2008 <u>Am J Dermatopathol. 2008 Apr;30(2):117-22.</u>	Not a study of the prognosis of PHH3.
Takei et al.	2007 <u>Arch Pathol Lab Med. 2007 Feb;131(2):234-41.</u>	Review



---

Romani et al.	2007 <u>BMC Cancer. 2007 Dec 21;7:232.</u>	Irrelevant research.
Kim et al.	2007 <u>Am J Clin Pathol. 2007 Jul;128(1):118-25.</u>	/
Kapur et al.	2007 <u>Arch Pathol Lab Med. 2007 Jan;131(1):57-64.</u>	Not a study of the prognosis of PHH3.
Yin et al.	2006 <u>Mod Pathol. 2006 Nov;19(11):1487-97. Epub 2006 Aug 4.</u>	Not a study of the prognosis of PHH3.
Tapia et al.	2006 <u>Am J Surg Pathol. 2006 Jan;30(1):83-9.</u>	Not a study of the prognosis of PHH3.
Liu et al.	2006 <u>J Neuropathol Exp Neurol. 2006 Sep;65(9):905-13.</u>	Not a study of the prognosis of PHH3.
Colman et al.	2006 <u>Am J Surg Pathol. 2006 May;30(5):657-64.</u>	Lack of survival analysis data (hazard risk estimate or survival curve of OS, RFS, DFS).
Ribalta et al.	2004 <u>Am J Surg Pathol. 2004 Nov;28(11):1532-6.</u>	Not a study of the prognosis of PHH3.

---

**Abbreviations:** PHH3= Phospho-histone-h3, OS = overall survival, DFS = disease-free survival, RFS = recurrence-free survival, TTP=time to progression, PFS=progression-free survival.